Investor FAQ

Frequently Asked Questions

Illumina, Inc., Investors Relations
5200 Illumina Way
San Diego, CA 92122

858.291.6421

ir@illumina.com

The Company’s common stock is traded on the NASDAQ Stock Market under the symbol ILMN.

The CUSIP number for Illumina’s common stock is 452327109.

Illumina has two convertible debt securities, which are as follows:

  • CUSIP number 452327AE9 with a maturity date of 6/15/2019
  • CUSIP number 452327AG4 with a maturity date of 6/15/2021

Illumina went public on July 28, 2000 at a price of $16.00, or $8.00 on a split-adjusted basis.

Illumina was incorporated in California in April 1998 and reincorporated in Delaware in July 2000.

To improve human health by unlocking the power of the genome.

The Company's fiscal year is 52 or 53 weeks ending the Sunday closest to December 31, with quarters of 13 or 14 weeks ending the Sunday closest to March 31, June 30, September 30, and December 31.

Computershare Trust Company, N.A. is Illumina’s stock transfer agent. Computershare contact information is as follows:

Computershare Trust Company, N.A.
250 Royall Street
Canton, MA 02021

Illumina common stock can be bought or sold through a stockbroker, bank or financial institution that offers brokerage services.

Illumina currently does not issue dividends and does not have a DRIP.

Illumina split its stock on September 23, 2008 on a 2-for-1 basis.

Typically, the Company's annual meeting is held in May, but the date is subject to change at the discretion of the Board of Directors.

Most of the Company's reports and financial filings can be printed or downloaded from the Financial Information section if this site.

Illumina’s upcoming earnings conference call information can be viewed on the Events & Presentations section of this site.

Illumina has more than ~7,000+ employees globally.

Illumina’s independent auditors are Ernst & Young LLP.

Future shareholder publications can be obtained by signing up on the E-mail Alerts section of this site.